
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

